Medivation Inc. (MDVN)

[bme]

What happens to MDVN shareholder after the acquisition if the shareholder did not sell MDVN shares? Thanks.

[MinnieM]

You are very welcome. ;)

Congrats on holding for that nice move. I'm waiting on it in a couple of mine.







In Reply to 'Shortmetina'
Thanks!

[Shortmetina]

Thanks!

[TheFinalCD]

just doesnt work that way


http://www.fool.com/knowledge-center/what-happens-to-a-companys-stock-when-a-buyout-is.aspx

[MinnieM]

Here's info on the tender offer.
http://ih.advfn.com/p.php?pid=nmona&article=72264548&symbol=MDVN

[MinnieM]

The big money move was already done by 4:15am ET.
67.16 close, 82 high premarket... congrats to all longs... ;)

Click on 2 day 15 minute pic to enlarge







In Reply to 'TopKnotchTrades'
So if buyout is at $81.50+....why is this at $80.40?

Does anyone know that? Seems like easy money for big hedge funds

[Investorr]

So if buyout is at $81.50+....why is this at $80.40?

Does anyone know that? Seems like easy money for big hedge funds

[T695]

It'll be at $84 at 6:30

[Shortmetina]

Deal or no deal??

http://www.shortmetina.com/watchlist-free.html

[MinnieM]

$MDVN - Pfizer is closing in on a $14B takeover of Medivation
https://twitter.com/KarinCAtrades/status/767496725023985664

Should be a nice pop in the morning.

[thetechtrader]

Harry has posted Charts of the Day video on MDVN at TheTechTrader site noting: Medivation, Inc. (MDVN) is looking really well. For the first time in about 6-7 weeks it actually spiked up with a breakaway gap, and moved back above the moving averages, spiked and closed at the highs for the day on Wednesday, up 3.16 to 60.95, or 5.47%, on 3.5 million shares. Technically, it needs to take out 62.87. http://tinyurl.com/hkj98y9

[venturecapp]

Sanofi Wants New Board Of Directors For Medivation http://marketexclusive.com/sanofi-sa-nysesny-names-new-board-directors-medivation-inc-nasdaqmdvn/7216/?icd1

[TSmith4659]

Why on earth would Fidelity, Vanguard and Blackrock, to name a few, want/accept a $52.50 bid?



TS

[$Pistol Pete$]

$MDVN Daily and Weekly Charts

[binks]

Looking good

[binks]

IBB happened

[Quokkie]

What happened to the pps??

[binks]

anyone in this?

[north40000]

8-k to activate a dead board:

http://ih.advfn.com/p.php?pid=nmona&article=67968198

[stocktrademan]

$MDVN DD Notes ~ http://www.ddnotesmaker.com/MDVN

bullish

$MDVN recent news/filings

## source: finance.yahoo.com

Tue, 02 Dec 2014 06:16:00 GMT ~ 1:16 am Medivation's XTANDI now approved in Europe for the treatment of men with metastatic castration-resistant prostate cancer who are chemotherapy-na ve


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#mdvn
*********************************************************

Tue, 02 Dec 2014 00:01:00 GMT ~ XTANDI™ (enzalutamide) Now Approved in Europe for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve


read full: http://uk.finance.yahoo.com/news/xtandi-enzalutamide-now-approved-europe-000100651.html
*********************************************************

Mon, 01 Dec 2014 06:00:00 GMT ~ US Federal Reserve will hike rates in June: Pro


read full: http://finance.yahoo.com/video/us-federal-hike-rates-june-060000861.html
*********************************************************

Fri, 28 Nov 2014 22:20:00 GMT ~ Newly Profitable Medivation Riding High On Drug Sales


read full: http://news.investors.com/112814-728337-newly-profitable-medivation-charges-higher.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************

Tue, 25 Nov 2014 21:34:03 GMT ~ Joseph Lobacki to Become Medivation's Chief Commercial Officer

[at noodls] - SAN FRANCISCO, CA -- (Marketwired) -- 11/25/14 -- Medivation, Inc. (NASDAQ: MDVN) today announced that Joseph Lobacki will join the company as chief commercial officer on December 8, 2014. In this position, ...

read full: http://www.noodls.com/view/A81F34CB01F97B1B41A43B16B797483746975F79
*********************************************************


$MDVN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$MDVN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/MDVN/company-info
Ticker: $MDVN
OTC Market Place: Not Available
CIK code: 0001011835
Company name: Medivation, Inc.
Incorporated In: DE, USA


$MDVN share structure

## source: otcmarkets.com

Market Value: $8,794,097,618 a/o Dec 02, 2014
Shares Outstanding: 77,624,659 a/o Oct 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$MDVN extra dd links

Company name: Medivation, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MDVN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MDVN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MDVN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/news - http://finance.yahoo.com/q/h?s=MDVN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MDVN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MDVN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MDVN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Medivation%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Medivation%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Medivation%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MDVN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001011835&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MDVN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MDVN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MDVN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MDVN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MDVN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MDVN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MDVN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MDVN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MDVN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MDVN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MDVN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MDVN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MDVN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MDVN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MDVN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MDVN



$MDVN DD Notes ~ http://www.ddnotesmaker.com/MDVN

[stocktrademan]

$MDVN DD Notes ~ http://www.ddnotesmaker.com/MDVN

bullish
ascending triangle breakout

$MDVN recent news/filings

## source: finance.yahoo.com

Mon, 25 Aug 2014 20:10:00 GMT ~ Medivation Announces Participation at Upcoming Investor Conference

[Marketwired] - Medivation, Inc. today announced that it will present at the following conference:

read full: http://finance.yahoo.com/news/medivation-announces-participation-upcoming-investor-201000398.html
*********************************************************

Mon, 25 Aug 2014 10:48:31 GMT ~ Can Medivation (MDVN) Run Higher on Strong Earnings Estimate Revisions?


read full: http://finance.yahoo.com/news/medivation-mdvn-run-higher-strong-104831940.html
*********************************************************

Fri, 15 Aug 2014 17:04:19 GMT ~ MEDIVATION, INC. Financials


read full: http://finance.yahoo.com/q/is?s=mdvn
*********************************************************

Mon, 11 Aug 2014 15:10:02 GMT ~ Medivation Jumps on Q2 Earnings Beat, Outlook Encourages


read full: http://finance.yahoo.com/news/medivation-jumps-q2-earnings-beat-151002266.html
*********************************************************

Mon, 11 Aug 2014 10:36:29 GMT ~ Medivation (MDVN) Jumps: Stock Adds 7.5% in Session


read full: http://finance.yahoo.com/news/medivation-mdvn-jumps-stock-adds-103629669.html
*********************************************************


$MDVN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$MDVN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/MDVN/company-info
Ticker: $MDVN
OTC Market Place: Not Available
CIK code: 0001011835
Company name: Medivation, Inc.
Incorporated In: DE, USA


$MDVN share structure

## source: otcmarkets.com

Market Value: $7,244,267,939 a/o Sep 09, 2014
Shares Outstanding: 76,788,933 a/o Aug 01, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$MDVN extra dd links

Company name: Medivation, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MDVN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MDVN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MDVN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/news - http://finance.yahoo.com/q/h?s=MDVN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MDVN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MDVN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MDVN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Medivation%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Medivation%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Medivation%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MDVN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001011835&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MDVN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MDVN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MDVN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MDVN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MDVN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MDVN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MDVN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MDVN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MDVN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MDVN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MDVN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MDVN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MDVN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MDVN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MDVN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MDVN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MDVN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MDVN



$MDVN DD Notes ~ http://www.ddnotesmaker.com/MDVN

[maytepper]

Maxim Maintains Buy On Medivation As Xtandi Continues To Exceed Expectations http://www.smarteranalyst.com/2014/08/04/maxim-maintains-buy-on-medivation-as-xtandi-continues-to-exceed-expectations/

[maytepper]

Janney Reiterates Buy On Medivation Following Astellas’ Xtandi Sales Report; Sees $110 Fair Value http://www.smarteranalyst.com/2014/08/01/janney-reiterates-buy-on-medivation-following-astellas-xtandi-sales-report-sees-110-fair-value/

[johnsyn]

thanks- and back up we go!

[TheFinalCD]

Data From PREVAIL Trial of Enzalutamide in Chemotherapy-Naive Metastatic Prostate Cancer to Be Presented in Late-Breaking Ses...







Print


Alert



Medivation, Inc. (MM) (NASDAQ:MDVN)
Intraday Stock Chart

Today : Thursday 19 December 2013
Click Here for more Medivation, Inc. (MM) Charts. Data From PREVAIL Trial of Enzalutamide in Chemotherapy-Naive Metastatic Prostate Cancer to Be Presented in Late-Breaking Session at ASCO GU Symposium
ASCO GU Names Abstract Among Four to Be Highlighted During 2014 Meeting


SAN FRANCISCO, CA and NORTHBROOK, IL--(Marketwired - Dec 19, 2013) - Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Global Development, Inc. announced that additional data from the Phase 3 PREVAIL trial evaluating enzalutamide in patients with chemotherapy-naïve metastatic prostate cancer will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2014 Genitourinary (GU) Cancers Symposium in San Francisco.

Details of the oral presentation are as follows:

Title: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of Phase 3 PREVAIL Study

Presenter: Tomasz M. Beer, OHSU Knight Cancer Institute, Oregon Health & Science University
•Session Detail: Welcome and General Session 1: Integrating Androgen Axis Therapy across the Disease Spectrum
•Session Date/Time: January 30, 2014 from 7:45 a.m - 9:45 a.m.

Two additional enzalutamide abstracts will be presented during General Poster Sessions:
•(Abstract #62) Enzalutamide monotherapy: Phase 2 study results in hormone-naïve prostate cancer patients. Presenter: Bertrand Tombal, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc (11:30 a.m. - 1:00 p.m., Thursday, January 30, 2014)
•(Abstract #247) Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone. Presenter: Mark Creamer Scholz, Prostate Oncology Specialists (12:00 - 1:30 p.m., Friday, January 31, 2014)

[TheFinalCD]

Thanks

Message in reply to:

Q3 conference call transcript



http://www.earningsimpact.com/Transcript/84463/MDVN/Medivation%2c-Inc----Q3-2013-Earnings-Call

[ECole]

Q3 conference call transcript



http://www.earningsimpact.com/Transcript/84463/MDVN/Medivation%2c-Inc----Q3-2013-Earnings-Call

[johnsyn]

8:24 AM UBS thinks data from a Phase III study will "suggest a greater magnitude of overall survival benefit" for Medivation's (MDVN) Xtandi than for Janssen's (JNJ) Zytiga. Analyst Matthew Roden upgrades MDVN to Buy and hikes his price target to $74 from $59

[ECole]

Presents at JMP Securities Healthcare Conference

Interesting presentation.. talks about XTANDI and more

Read here

[johnsyn]

4:13 PM Medivation (MDVN): Q1 EPS of -$0.36 beats by $0.02. Revenue of $46.15M beats by $7.61M.

[johnsyn]

2:07 PM Medivation (MDVN -7%) slides today, despite posting a better than expected Q4 result yesterday. Collaboration revenue was $37.2M, more than the $34.4M in Q4 revenue analysts had expected. For FY13 the company expects operating expenses net of cost-sharing payments from Astellas, to be between $285M and $300M, approximately $29M of which consists of non-cash stock-based compensation expense. The company continues to expect approximately $7M in capital expenditures in 2013.

[johnsyn]

4:15 PM Medivation (MDVN): Q4 EPS of -$0.43 beats by $0.09. Revenue of $57.4M beats by $23.04M.

[johnsyn]

12:59 PM Medivation (MDVN +1.2%) gains today after presenting data for its monotherapy enzalutamide, showing it's treatment on prostate cancer has positive results. The study showed that the treatment increased serum testosterone by a mean of 114% at week 25 as compared to its baseline, and the median change in PSA was -99.6%

[johnsyn]

12:20 PM Medivation (MDVN +3.4%) moves up today after its Japanese alliance partner Astellas Pharma reported in its financial results last night that it expects Xtandi sales to exceed year-end net sales targets ending on March 31. MDVN is due to report at the end of February. Separately, Jefferies raises its price target on the shares from $62 to $64

[johnsyn]

Xtandi Off to a Fast Start (MDVN) - Leerink Swann

7:23 AM 11/12/2012 - StreetInsider

Leerink Swann reiterated their Outperform rating on Medivation (NASDAQ: MDVN), saying Xtandi appears to be off to a fast start.

The firm comments, "As previously reported by Astellas and in an 8-K by MDVN, US Xtandi sales were $14.1M for the 12 shipping days in the 3Q12. We believe this represents a good start of the commercial launch, though a substantial portion was likely related to stocking and patients rolling over from the EAP. MDVN announced that Phase III clinical trials for Xtandi are being planned, although the indications are in discussion with partner Astellas and will be publicly announced at a later date."

Shares of Medivation closed at $45.70 yesterday, with a 52 week range of $38.82-$113.00. (NOTE- high was from pre-split)

[johnsyn]

4:16 PM Medivation (MDVN): Q3 EPS loss of $0.06 misses by $0.02. Revenue of $64.8M beats by $16M. (

[johnsyn]

Key House Health Subcommittee Will Have New Leaders Next Year

By Sue Darcey / Email the Author / Health News Daily Nov. 8, 2012
Today's Stories / Word Count: 688 / Article # 29121107004
Executive Summary

The almost-40-year House veteran Pete Stark, D-Calif., who served as ranking member of the House Ways and Means Health Subcommittee, was defeated in his re-election bid on Tuesday. And Wally Herger, R-Calif., who chaired the subcommittee, already announced his plans to retire earlier this year.

[johnsyn]

MDVN RAISES A/S FROM 50 MILLION TO 170 MILLION. Also 2:1 split completed after hours on last Friday.

[johnsyn]

Medivation and Astellas Announce XTANDI(R) (Enzalutamide) Is Now Available for Patients With Metastatic Castration-Resistant ...
Date : 09/13/2012 @ 7:00AM


Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced the availability of XTANDI® (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI was approved by the U.S. Food and Drug Administration (FDA) on August 31, 2012. XTANDI is being distributed through a network of specialty pharmacies and specialty distributors.

"XTANDI was approved by the FDA nearly three months ahead of the action date and we are proud of our accelerated efforts to get this new treatment option to patients with metastatic castration-resistant prostate cancer who have previously received docetaxel," said David Hung, M.D., co-founder, president and chief executive officer, Medivation, Inc. "Together with Astellas, we are excited to deliver this life extending therapy to patients in the United States."

Astellas and Medivation also announced the launch of a comprehensive patient access support program for XTANDI capsules to ensure patients who are prescribed XTANDI can access the drug in a timely manner. The new program, XTANDI Access Services(SM), will provide access and reimbursement support to physicians and patients and assist eligible patients without insurance. Examples of support available through this program include help with benefit verification and prior authorization, patient referral to independent non-profit organizations that can assist with out-of-pocket expenses, and prescription forwarding to specialty pharmacies in the network.

"It is our goal that this comprehensive set of services will help patients obtain access to XTANDI, regardless of their financial situation," said Mark Reisenauer, Vice President of Oncology Sales and Marketing, Astellas.

"We applaud the efforts that resulted in XTANDI becoming available to patients so quickly, and are pleased that a comprehensive access program is simultaneously available to help men and their physicians obtain this important new therapy," said Wendy Poage, president, Prostate Conditions Education Council.

XTANDI Access Services may be contacted Monday through Friday from 9:00 a.m. to 8:00 p.m. ET at 1-855-8XTANDI (1-855-898-2634) or by visiting www.XtandiAccess.com.

About XTANDI

XTANDI is an oral, once-daily androgen receptor inhibitor. XTANDI was approved by the FDA on August 31, 2012 for the treatment of metastatic castration-resistant prostate cancer for patients who have previously received docetaxel (chemotherapy).

The recommended dose of XTANDI is 160 mg (four 40 mg capsules) administered orally once daily. XTANDI can be taken with or without food and does not require concomitant steroid (e.g., prednisone) use. In the phase 3 clinical trial, 48% of XTANDI patients and 46% of patients in the placebo arm were treated with glucocorticoids.

The efficacy and safety of XTANDI were assessed in a randomized, placebo-controlled, multicenter phase 3 clinical trial. A total of 1,199 patients with mCRPC who had previously received docetaxel were randomized 2:1 to receive either XTANDI orally at a dose of 160 mg once daily (N = 800) or placebo (N = 399). Patients with a history of seizure, taking medications known to decrease the seizure threshold, or with other risk factors for seizure were excluded from the clinical trial. The primary endpoint of the trial was overall survival.

XTANDI-treated patients had a statistically-significant improvement in median overall survival compared to the placebo group: 18.4 months in the XTANDI group versus 13.6 months in the placebo group (P < 0.0001). XTANDI provided a 37% reduction in risk of death compared to placebo (hazard ratio = 0.631). Seizure occurred in 0.9% of patients on XTANDI and 0% of the placebo-treated patients. The most common adverse reactions (= 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients.

XTANDI Mechanism of Action

XTANDI (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. XTANDI has been shown to competitively inhibit androgen binding to androgen receptors, inhibit androgen receptor nuclear translocation and interaction with DNA. A major metabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to XTANDI. XTANDI decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.

Important Safety Information for XTANDI

Contraindications- XTANDI can cause fetal harm when administered to a pregnant woman based on its mechanism of action. XTANDI is not indicated for use in women. XTANDI is contraindicated in women who are or may become pregnant.

Warning and Precautions- In the randomized phase 3 clinical trial, seizure occurred in 0.9% of patients on XTANDI. No patients on the placebo arm experienced seizure. Patients experiencing a seizure were permanently discontinued from therapy. All seizures resolved. Patients with a history of seizure, taking medications known to decrease the seizure threshold, or with other risk factors for seizure were excluded from the clinical trial. Because of the risk of seizure associated with XTANDI use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.

Adverse Reactions- The most common adverse drug reactions (= 5%) reported in patients receiving XTANDI in the randomized clinical trial were asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.

Drug Interactions- Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. Administration of strong CYP2C8 inhibitors can increase the plasma exposure to XTANDI. Co-administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible. If co-administration of XTANDI cannot be avoided, reduce the dose of XTANDI. Co-administration of XTANDI with strong or moderate CYP3A4 and CYP2C8 inducers can alter the plasma exposure of XTANDI and should be avoided if possible. Avoid CYP3A4, CYP2C9 and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.

For Full Prescribing Information, please visit www.XtandiHCP.com.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.

About Astellas Pharma Inc.

Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global category leader in oncology, and has several oncology compounds in development in addition to XTANDI. For more information on Astellas Pharma Inc., please visit our website at www.astellas.com/en.

Medivation Contacts:

Patrick Machado

Chief Business & Financial Officer

[phone]



Anne Bowdidge

Senior Director, Investor Relations

[phone]



Astellas Contacts:

Jenny Kite

Corporate Communications

[phone]



Mike Beyer

Sam Brown, Inc (media for both companies)

[phone]

[johnsyn]

2:11 PM Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of its prostate cancer drug Xtandi by the FDA. Wedbush says that ultimately Xtandi will surpass Zytiga in sales and the pre-chemotherapy data for the drug is going to make it the market leader. SA

[johnsyn]

wow! all the analysts this morning are increasing price target to $122 at cheapest, $134 at high end.

[johnsyn]

Medivation Receives FDA Approval For XTANDI Capsules - Quick Facts


(RTTNews.com) - Medivation, Inc. (MDVN) and Astellas Pharma Inc. (ALPMF.PK) announced that the U.S. Food and Drug Administration or FDA has granted approval to XTANDI capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Medivation and Astellas expect to make XTANDI available to patients in the United States in mid-September 2012.

Medivation said that the FDA accepted the XTANDI New Drug Application or NDA on July 23, 2012, and granted the filing Priority Review Designation with a Prescription Drug User Fee Act or PDUFA action date of November 22, 2012.

XTANDI is an oral, once-daily androgen receptor inhibitor. The efficacy and safety of XTANDI were assessed in a randomized, placebo-controlled, multicenter phase 3 clinical trial. A total of 1,199 patients with mCRPC who had previously received docetaxel were randomized 2:1 to receive either XTANDI orally at a dose of 160 mg once daily or placebo, the company said.

Patients with a history of seizure, taking medications known to decrease the seizure threshold, or with other risk factors for seizure were excluded from the clinical trial. The primary endpoint of the trial was overall survival.

XTANDI-treated patients had a statistically-significant improvement in median overall survival compared to the placebo group. 18.4 months in the XTANDI group versus 13.6 months in the placebo group, Medivation noted.

For comments and feedback: contact [e-mail]

http://www.rttnews.com

[johnsyn]

nice pop. hope it holds for split

[mlkrborn]

Medivation confirms FDA approved XTANDI (enzalutamide) after priority review for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (MDVN) 98.78 +1.36 : Co and Astellas Pharma (ALPMY.PK) announced that the FDA has granted approval to XTANDI (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor. The FDA accepted the XTANDI New Drug Application (NDA) on July 23, 2012, and granted the filing Priority Review Designation with a Prescription Drug User Fee Act (PDUFA) action date of November 22, 2012. Medivation and Astellas expect to make XTANDI available to patients in the United States in mid-September 2012, and the specific availability date will be announced on www.XtandiHCP.com as soon as it is known. Separately, a Marketing Authorization Application for XTANDI has been accepted for review by the European Medicines Agency. As a post-marketing requirement, Medivation and Astellas have agreed with the FDA to conduct an open-label safety study of XTANDI (160 mg/day) in patients who are at high risk for seizure. Medivation and Astellas have agreed to provide the data from this study in 2019.

[johnsyn]

Medivation plans 2-for-1 stock split on Sept. 21

5:37 PM 8/28/2012 - AcquireMedia

SAN FRANCISCO -- Drugmaker Medivation Inc. said Tuesday that it will conduct a two-for-one stock split on Sept. 21.

The company said stockholders who own Medivation shares as of Sept. 7 will get one additional share for each share they own. The split will take effect when trading begins on Sept. 24. The split will double the company's outstanding number of shares and halve its share price, potentially making the stock more attractive to investors.

Medivation had 36.8 million shares on the market as of Aug. 3. The company's shares trade on the Nasdaq Global Market.

Shares of Medivation lost 23 cents to close at $96.17 Tuesday. The stock surged in November on positive clinical trial data for its prostate cancer pill enzalutamide, and continued to climb on results from a second trial in February. The shares reached an all-time high of $103.89 on July 27.

The Food and Drug Administration has not yet approved enzalutamide, but Medivation and its partner Astellas Pharma say they could launch the drug later this year.

[johnsyn]

It is still about 3.5% lower than what I sold it at. Hmmm.

[V63]

the way i see it it will probabply split in two of about close to 50 bucks far from last year which was around 20 dollars and even cheaper so if you buy now you will gain more before the PPS rises by sept. unless it starts to go the south course which by looking at the chart seems unlikely.

[johnsyn]

and I have, not even a year. A shame I sold half at near 300% profit, now with the forward split, gain them back anyway, buy could have been extremely happy with selling that half after Sept 7.

[johnsyn]

Medivation Announces a 2-for-1 Forward Split of Its Common Stock

Today : Wednesday 29 August 2012

Medivation, Inc. (NASDAQ: MDVN) today announced a 2-for-1 forward split of its common stock with a Record Date of September 7, 2012. The forward split will take effect on the Payable Date, September 21, 2012, and Medivation's common stock will begin trading on a post-split basis on the NASDAQ Global Market on September 24, 2012.

On the Payable Date, every one (1) share of the Company's pre-split common stock held by a shareholder as of the Record Date, including shares subject to outstanding stock options and shares available for grant under the Company's equity incentive plans, will automatically be split into two (2) shares of the Company's post-split common stock. The forward split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage. Additional information regarding the forward split can be found in Medivation's definitive proxy statement filed with the Securities and Exchange Commission on June 1, 2012.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.

Contacts:

Patrick Machado

Chief Business & Financial Officer

[phone]



Anne Bowdidge

Sr. Director, Investor Relations

[phone]

[V63]

those who held for a year sure made a lot of money now with a forward split we have a secound chance a little higher but if it comes back up theres still good money to be made here this here from earlier this month shows they are heading into the right direction and quite possibly will make it back up if the continue doing a great job ET
(RTTNews) - Medivation Inc. (MDVN:Quote) Thursday reported a narrower loss for the second quarter, due mainly to higher revenues.

The San Francisco, California-based company's second-quarter net loss was $5.50 million or $0.15 per share, compared to $9.47 million or $0.27 per share last year. On average, 12 analysts polled by Thomson Reuters expected the company to earn $0.20 per share for the quarter. Analysts' estimates typically exclude special items.

Total collaboration revenues for the quarter grew to $42.91 million from $15.80 million in the prior-year quarter. Twelve analysts had a consensus revenue estimate of $46.96 million for the quarter.